Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 2 |
2023 | 3 |
2024 | 2 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Signal Transduct Target Ther. 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3.
Signal Transduct Target Ther. 2022.
PMID: 35185150
Free PMC article.
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M.
Jia Y, et al. Among authors: ramage cl.
Haematologica. 2023 Oct 1;108(10):2626-2638. doi: 10.3324/haematol.2022.281915.
Haematologica. 2023.
PMID: 37078252
Free PMC article.
Item in Clipboard
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
Hurrish KH, Su Y, Patel S, Ramage CL, Carter JL, Edwards H, Buck SA, Wiley SE, Hüttemann M, Polin L, Kushner J, Dzinic SH, White K, Bao X, Li J, Yang J, Boerner J, Hou Z, Al-Atrash G, Konoplev SN, Busquets J, Tiziani S, Matherly LH, Taub JW, Konopleva M, Ge Y, Baran N.
Hurrish KH, et al. Among authors: ramage cl.
Res Sq [Preprint]. 2023 Apr 28:rs.3.rs-2843025. doi: 10.21203/rs.3.rs-2843025/v1.
Res Sq. 2023.
PMID: 37162954
Free PMC article.
Updated.
Preprint.
Item in Clipboard
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML.
Mohanty V, Baran N, Huang Y, Ramage CL, Cooper LM, He S, Iqbal R, Daher M; CTD2 Research Network; Tyner JW, Mills GB, Konopleva M, Chen K.
Mohanty V, et al. Among authors: ramage cl.
bioRxiv [Preprint]. 2024 Jan 30:2024.01.27.577579. doi: 10.1101/2024.01.27.577579.
bioRxiv. 2024.
PMID: 38352538
Free PMC article.
Preprint.
Item in Clipboard
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
Hurrish KH, Su Y, Patel S, Ramage CL, Zhao J, Temby BR, Carter JL, Edwards H, Buck SA, Wiley SE, Hüttemann M, Polin L, Kushner J, Dzinic SH, White K, Bao X, Li J, Yang J, Boerner J, Hou Z, Al-Atrash G, Konoplev SN, Busquets J, Tiziani S, Matherly LH, Taub JW, Konopleva M, Ge Y, Baran N.
Hurrish KH, et al. Among authors: ramage cl.
Biochem Pharmacol. 2024 Feb;220:115981. doi: 10.1016/j.bcp.2023.115981. Epub 2023 Dec 10.
Biochem Pharmacol. 2024.
PMID: 38081370
Item in Clipboard
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M.
Zhang Q, et al. Among authors: ramage cl.
Signal Transduct Target Ther. 2022 Apr 1;7(1):110. doi: 10.1038/s41392-022-00958-4.
Signal Transduct Target Ther. 2022.
PMID: 35365596
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite